Vance Marc Zemon

Dr. Vance Marc Zemon

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2016 in Brain Research
Verified
Journal Article
Closed access
JMJeannette R. Mahoney
Jeannette R. Mahoney
RHRoee Holtzer
Roee Holtzer
MIMeltem Izzetoglu
Meltem Izzetoglu
VZVance Marc Zemon
Vance Marc Zemon
JVJoe Verghese
Joe Verghese
GAGilles Allali
Gilles Allali

1 November 2006 in Vision Research
Verified
Journal Article
Closed access
VZVance Marc Zemon
Vance Marc Zemon
JGJames Gordon
James Gordon

28 October 2020 in European Journal of Neuroscience
Verified
Journal Article
Closed access
PDF file
VZVance Marc Zemon
Vance Marc Zemon
SHShaynna Herrera
Shaynna Herrera
JGJames Gordon
James Gordon
NRNadine Revheim
Nadine Revheim
GSGail Silipo
Gail Silipo
PBPamela D. Butler
Pamela D. Butler

16 May 2008 in Documenta Ophthalmologica
Verified
Journal Article
Closed access
PDF file
VZVance Marc Zemon
Vance Marc Zemon
JTJames C. Tsai
James C. Tsai
MFMax Forbes
Max Forbes
LALama A. Al-Aswad
Lama A. Al-Aswad
CCChi-Ming Chen
Chi-Ming Chen
LJLawrence F. Jindra
Lawrence F. Jindra

1 January 2022 in Journal of Psychiatric Research
Verified
Journal Article
Closed access
CNChayim Newman
Chayim Newman
RGRyan P. George
Ryan P. George
TBTim Beitz
Tim Beitz
ZBZachary Bergson
Zachary Bergson
VZVance Marc Zemon
Vance Marc Zemon

9 June 2016 in The Clinical Neuropsychologist
Verified
Journal Article
Closed access
EGElizabeth S. Gromisch
Elizabeth S. Gromisch
VZVance Marc Zemon
Vance Marc Zemon
RHRoee Holtzer
Roee Holtzer
NCNancy D. Chiaravalloti
Nancy D. Chiaravalloti
JDJohn DeLuca
John DeLuca
FFFrederick W. Foley
Frederick W. Foley
Objective: Cognitive dysfunction is prevalent in multiple sclerosis. As self-reported cognitive functioning is unreliable, brief objective screening measures are needed. Utilizing widely used full-length neuropsychological tests, this study aimed to establish the criterion validity of highly abbreviated versions of the Brief Visuospatial Memory Test – Revised (BVMT-R), Symbol Digit Modalities Test (SDMT), Delis–Kaplan Executive Function System (D-KEFS) Sorting Test, and Controlled Oral Word Association Test (COWAT) in order to begin developing an MS-specific screening battery. Method: Participants from Holy Name Medical Center and the Kessler Foundation were administered one or more of these four measures. Using test-specific criterion to identify impairment at both −1.5 and −2.0 SD, receiver-operating-characteristic (ROC) analyses of BVMT-R Trial 1, Trial 2, and Trial 1 + 2 raw data (N = 286) were run to calculate the classification accuracy of the abbreviated version, as well as the sensitivity and specificity. The same methods were used for SDMT 30-s and 60-s (N = 321), D-KEFS Sorting Free Card Sort 1 (N = 120), and COWAT letters F and A (N = 298). Results: Using these definitions of impairment, each analysis yielded high classification accuracy (89.3 to 94.3%). Conclusions: BVMT-R Trial 1, SDMT 30-s, D-KEFS Free Card Sort 1, and COWAT F possess good criterion validity in detecting impairment on their respective overall measure, capturing much of the same information as the full version. Along with the first two trials of the California Verbal Learning Test – Second Edition (CVLT-II), these five highly abbreviated measures may be used to develop a brief screening battery.